Janssen Search
Search results
James F. List, M.D., Ph.D.
JAMES F. LIST, M.D., PH.D. GLOBAL THERAPEUTIC AREA HEAD CARDIOVASCULAR & METABOLISM James F. List, M.D., Ph.D., is the Global Therapeutic Area Head of Cardiovascular & Metabolism (CVM), leading a global team focused on creating new solutions for ...
James List, M.D., Ph.D.
JAMES LIST, M.D., Ph.D. GLOBAL THERAPEUTIC AREA HEAD CARDIOVASCULAR & METABOLISM James F. List, M.D., Ph.D. is the Global Therapeutic Area Head of Cardiovascular & Metabolism (CVM), leading a global team focused on creating new solutions for ...
Peter M. DiBattiste, M.D.
Peter M. DiBattiste, M.D. is responsible for co-leading the Cardiovascular & Metabolism (CVM) Therapeutic Area at Janssen Research & Development, setting the strategy and leading the team in discovery and development of novel therapeutics for ...
Robert Yang, Ph.D.
ROBERT YANG, PH.D. GLOBAL HEAD DATA SCIENCES & PREVENTION BIOMARKERS WORLD WITHOUT DISEASE ACCELERATOR As Global Head, Data Sciences & Prevention Biomarkers, World Without Disease Accelerator (WWDA), Robert leads a team focused on developing ...
Kevin Hamill
KEVIN HAMILL VICE PRESIDENT JANSSEN BUSINESS DEVELOPMENT IMMUNOLOGY Kevin Hamill is Vice President, Business Development for the Immunology Therapeutic Area (TA) at Johnson & Johnson Innovation, Janssen Business Development. In this role, he leads all ...
Biopharma Leaders Unite To Stand With Science
Sep 08, 2020 United States Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines NEW YORK, September 8, 2020 — The CEOs of AstraZeneca (LSE ...